An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

Trial Profile

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 26 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 11 May 2015 Planned End Date changed from 1 May 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top